Cortagen

Learn about Cortagen, a Khavinson peptide supporting central nervous system research and immune modulation.

Educational summaryPeptide research profile

(how we review)

Dosing & scaling, explained

The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.

Mass amounts available for comparison

  1. Lower range1 mgDose

    Recorded example with no verified study backing; shown for amount literacy only.

  2. Mid range5 mgDose

    Recorded example with no verified study backing; shown for amount literacy only.

Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.

No independently verified schedule

Evidence context

No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.

Storage, handling and interpretation

Product identity

Verify the exact compound, formulation and amount against the product label or certificate before calculation.

Storage & handling

Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.

Prepared solutions

Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.

Reported protocols for Cortagen

What published studies and recent community write-ups report about amounts, timing and course length. 2 preclinical and 6 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.

ContextDoseFrequencyRouteCourseSource
Preclinical2 rows
Rat sciatic nerve regenerationRats after transection and suturing of the sciatic nerve10 mcg/kgOnce daily for 10 daysIntramuscular10 days of injections, with regeneration assessed months laterNot applicableBulletin of Experimental Biology and Medicine (PubMed)2000
Treated rats showed a 27% higher growth rate of regenerating fibers and a 40% higher conduction velocity than controls. Only the abstract is indexed, the work comes from the originating institute, and a 2002 follow-up on delayed effects has no abstract at all; no group outside Russia has repeated the model.
Mouse locomotor and anxiety behaviourCD-1 mice tested in the elevated plus maze and locomotor habituation paradigms0.01, 0.03 or 0.10 mg/kg (Cortexin 0.25 mg/kg as reference)Single injection, then a 5-day sub-chronic regimenIntraperitoneal5 daysNot applicableThe Open Neuropsychopharmacology Journal (Bentham Open)2011
The 0.03 mg/kg dose increased locomotion both acutely and after five days with little effect on anxiety measures, while the other doses and the Cortexin reference became anxiogenic after repeated dosing. This Istituto Superiore di Sanita study is the only Cortagen experiment from outside the Khavinson group, and the authors' remark that peptides act at very low doses without side effects rests on behaviour in mice.
Community-reported6 rows
Community injectable course by goal1-3 mg (general); 5-10 mg (neurological support); 1 mg conservative startOnce daily, morningSubcutaneous10-20 days (10 days for the conservative start)Repeated every 3-6 monthsCommunity resource2026
A 2026 dosage guide tiers the course by goal, with 1-3 mg a day for cognitive maintenance and 5-10 mg a day for age-related decline or recovery after cerebrovascular events, and sets 10 mg a day as a ceiling because nothing above it has been described. It attributes the ranges to Khavinson protocols and Russian clinical use without citing a dosed study, and PubMed holds none.
Oral capsules and intranasal alternatives10 mg capsules; 1-3 mg intranasalCapsules 1-2 times daily; intranasal once dailyOral or intranasal10-30 days (oral); 10-20 days (intranasal)Same 3-6 month spacing as the injectable courseCommunity resource2026
The same guide lists 10 mg capsules sold in Russia at one or two a day for 10-30 days, explaining the longer course as compensation for lower oral bioavailability, and an intranasal 1-3 mg variant it concedes has less data. No absorption study exists for either route, so the comparison between them is reasoning rather than measurement.
Research-context versus community figures1-10 mg (described as research-context); 100-500 mcg (community); 10-20 mg oralOnce dailySubcutaneous, or oral capsules10-20 daysCourses repeated 1-3 times per year, typically spring and autumnCommunity resource2026
A 2026 reference page separates three bands: 1-10 mg a day attributed to Russian-language clinical summaries, 100-500 mcg a day as the community habit, and 10-20 mg a day for capsules whose bioavailability has never been measured. It states that no validated human dose exists and that no pharmacokinetic value of any kind has been published for Cortagen.
Low-dose community pattern100-500 mcgOnce dailySubcutaneous10-20 days per courseNot specifiedCommunity resource2026
An evidence-review site records 100-500 mcg a day for 10-20 days as the commonly referenced research-community protocol and calls it an extrapolation from general Khavinson peptide habits rather than anything Cortagen-specific. It notes that the one in vivo mouse study it discusses dosed for 5 days and gives no amount in its abstract.

How a course is commonly described

  1. Days 1-10Community-reported

    Community guides describe starting at the full dose on day one, injected subcutaneously in the morning, with 10 days as the standard course and 1 mg a day as the conservative first course. They tell readers to expect nothing acute, framing the course as a gene-expression pulse rather than a drug with same-day effects.

  2. Days 11-20Community-reported

    Extended courses of 15-20 days are described for neurological support at the higher 5-10 mg tier, and capsule courses run to 30 days. No source describes a taper or any marker for judging the course.

  3. Months 1-6 offCommunity-reported

    A break of 3-6 months follows, during which guides claim the gene-expression changes are doing their work, and they describe the most noticeable results arriving only after two or three cycles spread over 12-18 months. None of this has been measured in people.

  4. Repeat coursesCommunity-reported

    Courses are described as repeating one to three times a year, often in spring and autumn, following the seasonal pattern used across the Khavinson peptide family rather than anything specific to Cortagen.

  5. Preclinical comparisonPreclinical

    The rat study gave 10 mcg/kg intramuscularly for 10 days and measured nerve regrowth months afterwards, and the mouse behavioural study dosed for 5 days at 0.01-0.10 mg/kg. Both are far below the community milligram courses once scaled to body weight, and neither tested repeat courses.

  • The only dosed data are rodent: 10 mcg/kg intramuscularly for 10 days in rats and 0.01-0.10 mg/kg intraperitoneally in mice. The body-surface-area human equivalent of the rat dose is about 1.6 mcg/kg, which works out to roughly 0.1 mg for a 70 kg adult, well under the 1-10 mg daily courses described by community guides.
  • No pharmacokinetic study exists in any species, so claims that Cortagen clears within minutes are class assumptions about short peptides rather than measurements, and nothing is known about repeated courses.
  • Cortagen is not approved outside Russia and neighbouring countries and no trial is registered. The human reports are Russian-language, uncontrolled and combine it with the extract Cortexin, so the courses above record what guides describe, not tested regimens.
Sources for this section (11)
  1. Effect of tetrapeptide cortagen on regeneration of sciatic nerveBulletin of Experimental Biology and Medicine (PubMed)2000Preclinical
  2. The delayed effect of cortagen on the restoration of injured nerve functionDoklady Biological Sciences (PubMed)2002Preclinical
  3. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarrayNeuro Endocrinology Letters (PubMed)2004Preclinical
  4. Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia (Russian)Eksperimentalnaia i Klinicheskaia Farmakologiia (PubMed)2011Preclinical
  5. Tissue-specific effects of peptidesBulletin of Experimental Biology and Medicine (PubMed)2001Preclinical
  6. Modulatory Effects of Cortexin and Cortagen on Locomotor Activity and Anxiety-Related Behavior in MiceThe Open Neuropsychopharmacology Journal (Bentham Open)2011Preclinical

Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.

Overview

Cortagen is the synthetic tetrapeptide Ala-Glu-Asp-Pro (AEDP), designed by Vladimir Khavinson's group from the amino acid composition of Cortexin, a bovine cerebral cortex extract used clinically in Russia, and sold as the cerebral cortex member of the bioregulator family. It has the most concrete animal result in that family: a 2000 rat study in which 10 mcg/kg intramuscularly for 10 days after sciatic nerve transection sped fiber regrowth and conduction velocity, followed by rat work in chronic brain ischemia, a mouse heart gene expression study and an Italian mouse behavioral study. Human evidence is limited to Russian-language reports that pair it with Cortexin; there is no controlled trial, no pharmacokinetic study and no registered trial, it is not approved outside Russia and neighbouring countries, and the milligram courses sold online come from community convention rather than from any dosed study.

What researchers are exploring

These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.

  • 1

    Chromatin & Gene Expression

    Mechanistic findings from transcriptome studies

  • 2

    Oxidative Balance & Neuroprotection

    Antioxidant and anti-inflammatory activity

  • 3

    Nerve Regeneration

    Impact on peripheral nerve repair

  • 4

    Summary

    Therapeutic considerations

What is known and what still needs verification

Available context is organized without assigning unsupported study models or evidence grades.

  • Not graded

    Chromatin & Gene Expression

    Mechanistic findings from transcriptome studies

  • Not graded

    Oxidative Balance & Neuroprotection

    Antioxidant and anti-inflammatory activity

Amounts recorded for Cortagen

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 1
    Dose · lower endpointSign in for schedule, duration and source context.
    1 mg
  • 2
    Dose · upper endpointSign in for schedule, duration and source context.
    5 mg

Chemistry identifiers

Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.

Sequence

Ala-Glu-Asp-Pro

Also listed as

Cortagen, Ala-Glu-Asp-Pro, AEDP (code used in the papers), SCHEMBL5491754, EX-A16854

InChIKey

PLTRIMAUDDQYRV-NAKRPEOUSA-N

IUPAC name

(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carboxylic acid

Limitations and unknowns

Important limitations

  • Individual claims and source links have not yet completed editorial verification.
  • Evidence level, applicable study model, formulation, route and population remain unassigned.

Sources

1 link carried over from the earlier page, awaiting verification.

  1. Source link (pmc.ncbi.nlm.nih.gov)Verification pendingNot graded